Treatment of patients with late-life major depression study

This study is a 25-week trial for the evaluation of safety and effectiveness of an FDA-approved medication versus placebo in subjects with late-life major depression. The trial begins with a screening period in which subjects are evaluated for entry into the study treatment period.  Subjects are then randomly assigned to study drug or placebo and treated for 13-weeks. Study treatment may then be continued for an additional 12 weeks or switched, depending on the subject’s response after the initial 13 weeks of treatment. The last study period is a double-blind optional two-week period where study drug can be slowly discontinued.

You may be eligible to participate in this study if you:

• Are a male or female of age 65 years or older
• Meet criteria for major depression
• Have had at least one prior episode of major depression
• Agree not to participate in any other research trial or study while enrolled in this study
• Meet all other eligibility requirements as specified by the protocol
  

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via e-mail, please include the title of the study in your message.